NCT01922193 - Evaluation of Efficacy and Safety of Highly Purified Urofollitropin in Chinese Females Undergoing an Assisted Reproductive Technology (ART) Program | Biotech Hunter

Enrollment

263

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

February 28, 2015

Study Completion Date

April 30, 2015

Conditions

Infertility

Interventions

DRUG

Highly Purified Urofollitropin

for injection

DRUG

Recombinant Human Follitropin Alfa

for injection

Trial Locations (11)

Chinese PLA General Hospital, Beijing

Peking Union Medical College Hospital, Beijing

Peking University First Hospital, Beijing

Peking University People's Hospital, Beijing

Sun Yat-sen Memorial Hospital Sun Yat-sen University, Guangzhou

The third Affiliated Hospital of Guangzhou Medical University, Guangzhou

Tongji Hospital Tongji Medical College of HUST Tongji Medical College Huazhong University of Science & Technology, Wuhan

The First Affiliated Hospital with Nanjing Medical University, Nanjing

ShengJing Hospital of China Medical University, Shenyang

Sichuan Provincial People's Hospital, Chengdu

Tianjin Medical University General Hospital, Tianjin